Literature DB >> 10437990

Optimizing response to methadone maintenance treatment: use of higher-dose methadone.

S Maxwell1, M Shinderman.   

Abstract

Using signs, symptoms and serum methadone levels to guide evaluation, the authors treated 164 patients in a methadone maintenance program with doses of methadone exceeding 100 mg/d. The mean dose of these higher dose (HD) patients was 211 mg/d (range 110-780 mg/d). A comparison group (C) of 101 patients was randomly selected from the general clinic population (mean dose 65 mg/d). At intake the HD group reported $153/day of heroin use versus $87/day in the C group. The HD group had more patients whose opiate of choice was an oral pharmaceutical (30% versus 2% of the C group). Sixty-three percent of the HD group had comorbid Axis I psychiatric diagnoses compared to 32% of the C group. Response to psychopharmacologic treatment was enhanced by increased methadone dose in HD patients with "refractory" psychiatric disorders. Urine toxicologies described as "before" were collected prior to increase over 100 mg/d in the HD group or at the first routine urine toxicology collection of the calendar year for the C group. These results were compared to the most recent urine toxicologies for both groups ("after"). The percentage of toxicologies positive for illicit drugs in the HD group dropped from 87% "before" to 3% "after". The C group were 54% positive "before" and 37% positive "after". We conclude that doses of methadone in excess of 100 mg/d (range 110-780 mg/d in our sample of 164 patients) are not only safe but necessary to prevent illicit opiate use, stabilize psychiatric symptoms, and diminish abuse of alcohol and benzodiazepines in many patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10437990     DOI: 10.1080/02791072.1999.10471730

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  13 in total

Review 1.  Methadone tolerance testing in drug misusers.

Authors:  Adam Bakker; Cindy Fazey
Journal:  BMJ       Date:  2006-11-18

2.  Directly observed antiretroviral therapy eliminates adverse effects of active drug use on adherence.

Authors:  Shadi Nahvi; Alain H Litwin; Moonseong Heo; Karina M Berg; Xuan Li; Julia H Arnsten
Journal:  Drug Alcohol Depend       Date:  2011-08-31       Impact factor: 4.492

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.

Authors:  Leslie Lappalainen; Seonaid Nolan; Sabina Dobrer; Cathy Puscas; Julio Montaner; Keith Ahamad; Huiru Dong; Thomas Kerr; Evan Wood; M-J Milloy
Journal:  Addiction       Date:  2015-08       Impact factor: 6.526

5.  Pharmacotherapy in the treatment of addiction: methadone.

Authors:  Mary Jeanne Kreek; Lisa Borg; Elizabeth Ducat; Brenda Ray
Journal:  J Addict Dis       Date:  2010-04

Review 6.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 7.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment.

Authors:  Martha J Bojko; Alyona Mazhnaya; Ruthanne Marcus; Iuliia Makarenko; Zahedul Islam; Sergey Filippovych; Sergii Dvoriak; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2016-03-24

9.  Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response.

Authors:  Francina Fonseca; Rafael de la Torre; Laura Díaz; Antonio Pastor; Elisabet Cuyàs; Nieves Pizarro; Olha Khymenets; Magí Farré; Marta Torrens
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

10.  Determining effective methadone doses for individual opioid-dependent patients.

Authors:  Jodie A Trafton; Jared Minkel; Keith Humphreys
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.